Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Launay

Showing results (241-250 of 307) with videos related to

Pageof 31
Sort By:
Arthritis Research & Therapy|February 20, 2020
Early trajectories of skin thickening are associated with severity and mortality in systemic sclerosisEmmanuel Ledoult, David Launay, Hélène Béhal, et al.
Plos One|January 28, 2014
ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseasesGandhi Damaj, Magalie Joris, Olivia Chandesris, et al.
Journal of Autoimmunity|March 4, 2025
Total lung capacity is predictive of disease severity and survival in systemic sclerosis: A longitudinal analysis in 2347 patients from the French National Cohort StudyBenjamin Chaigne, Alexandre Bense, Frédérique Aubourg, et al.
Annals of the Rheumatic Diseases|March 18, 2026
Risk score for early mortality to stratify for intensive SSc therapy in the EUSTAR network: the RESIST scoreAnn-Christin Pecher, Marouane Boubaya, Yannick Allanore, et al.
European Journal of Cancer (Oxford, England : 1990)|November 23, 2021
Anti-programmed death ligand 1 immunotherapies in cancer patients with pre-existing systemic sclerosis: A postmarketed phase IV safety assessment studyMarion Panhaleux, Olivier Espitia, Benjamin Terrier, et al.
Annals of Emergency Medicine|March 6, 2018
Specialist Advice Support for Management of Severe Hereditary Angioedema Attacks: A Multicenter Cluster-Randomized Controlled TrialNicolas Javaud, Olivier Fain, Isabelle Durand-Zaleski, et al.
American Journal of Hematology|June 16, 2026
The IL-10/IL-6 Ratio and the Risk Score: Two Cytokines-Based Predictors for Malignancy-Associated Hemophagocytic Lymphohistiocytosis in Adults (M-HLHa)Coralie Bloch, Stephanie Chhun, Nanthara Sritharan, et al.
Presse Medicale (Paris, France : 1983)|July 17, 2014
Lung and heart-lung transplantation for systemic sclerosis patients. A monocentric experience of 13 patients, review of the literature and position paper of a multidisciplinary Working GroupDavid Launay, Laurent Savale, Alice Berezne, et al.
Blood|August 11, 2012
High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytosesJulien Haroche, Frédéric Charlotte, Laurent Arnaud, et al.
Rheumatology (Oxford, England)|October 3, 2022
Determination of four homogeneous subgroups of patients with antiphospholipid syndrome: a cluster analysis based on 509 casesYann Nguyen, Cécile M Yelnik, Nathalie Morel, et al.
Pageof 31

Showing results (241-250 of 307) with videos related to

Sort By:
Pageof 31
Arthritis Research & Therapy|February 20, 2020
Early trajectories of skin thickening are associated with severity and mortality in systemic sclerosisEmmanuel Ledoult, David Launay, Hélène Béhal, et al.
Plos One|January 28, 2014
ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseasesGandhi Damaj, Magalie Joris, Olivia Chandesris, et al.
Journal of Autoimmunity|March 4, 2025
Total lung capacity is predictive of disease severity and survival in systemic sclerosis: A longitudinal analysis in 2347 patients from the French National Cohort StudyBenjamin Chaigne, Alexandre Bense, Frédérique Aubourg, et al.
Annals of the Rheumatic Diseases|March 18, 2026
Risk score for early mortality to stratify for intensive SSc therapy in the EUSTAR network: the RESIST scoreAnn-Christin Pecher, Marouane Boubaya, Yannick Allanore, et al.
European Journal of Cancer (Oxford, England : 1990)|November 23, 2021
Anti-programmed death ligand 1 immunotherapies in cancer patients with pre-existing systemic sclerosis: A postmarketed phase IV safety assessment studyMarion Panhaleux, Olivier Espitia, Benjamin Terrier, et al.
Annals of Emergency Medicine|March 6, 2018
Specialist Advice Support for Management of Severe Hereditary Angioedema Attacks: A Multicenter Cluster-Randomized Controlled TrialNicolas Javaud, Olivier Fain, Isabelle Durand-Zaleski, et al.
American Journal of Hematology|June 16, 2026
The IL-10/IL-6 Ratio and the Risk Score: Two Cytokines-Based Predictors for Malignancy-Associated Hemophagocytic Lymphohistiocytosis in Adults (M-HLHa)Coralie Bloch, Stephanie Chhun, Nanthara Sritharan, et al.
Presse Medicale (Paris, France : 1983)|July 17, 2014
Lung and heart-lung transplantation for systemic sclerosis patients. A monocentric experience of 13 patients, review of the literature and position paper of a multidisciplinary Working GroupDavid Launay, Laurent Savale, Alice Berezne, et al.
Blood|August 11, 2012
High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytosesJulien Haroche, Frédéric Charlotte, Laurent Arnaud, et al.
Rheumatology (Oxford, England)|October 3, 2022
Determination of four homogeneous subgroups of patients with antiphospholipid syndrome: a cluster analysis based on 509 casesYann Nguyen, Cécile M Yelnik, Nathalie Morel, et al.
Pageof 31